Conceptio › Archive › Google Patents

Google Patents open access

Crispr having or associated with destabilization domains — The Broad Institute, Inc. (US20260152731A1)

The Broad Institute, Inc. · Google Patents

Google Patents · Patents

en feng-zhang google-patents intellectual-property patent the-broad-institute

, wherein the stabilizing ligand comprises 4-hydroxytamoxifen (4HT) or CMP8. 11 . The method of claim 7 , wherein the Cas9 protein is fused to a first DHFR domain at the N-terminus and a second DHFR domain at the C-terminus. 12 . The method of claim 7 , wherein the DHFR domain comprises the amino acid … Crispr having or associated with destabilization domains — The Broad Institute, Inc. (US20260152731A1)

Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

Explore in Search →Connect via MCP / API ↗

ABSTRACT

Abstract

The disclosure includes non-naturally occurring or engineered CRISPR Cas9, each associated with at least one destabilization domain (DD), along with compositions, systems and complexes involving the DD-CRISPR Cas9, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses therefor.

Description

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

This application is a Continuation application of U.S. patent application Ser. No. 17/081,387, filed on Oct. 27, 2020, which is a Continuation application of U.S. patent application Ser. No. 15/633,126, filed Jun. 26, 2017, which is a Continuation-In-Part of International Patent Application No. PCT/US2015/067177 filed Dec. 21, 2015 and published as PCT Publication No. WO 2016/106244 on Jun. 30, 2016, which claims priority from U.S. Patent Application No. 62/096,656, filed Dec. 24, 2014, and U.S. Patent Application No. 62/181,151, filed Jun. 17, 2015.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grant nos. MH100706 and MI 10049 awarded by the National Institutes of Health. The government has certain rights in the invention.

Each of these patents, patent publications, and applications, and all documents cited therein or during their prosecution (âappln cited documentsâ) and all documents cited or referenced in the appln cited documents, together with any instructions, descriptions, product specifications, and product sheets for any products mentioned therein are incorporated by reference herein, and may be employed in the practice of the invention. Moreover, all documents cited or referenced herein (âherein cited documentsâ), and all documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. All referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on Feb. 20, 2026, is named 114203-5907_SL.xml and is 86,064 bytes in size.

FIELD OF THE INVENTION

The present invention generally relates to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), CRISPR enzyme (Cas9), CRISPR-Cas9 or CRISPR system or CRISPR-Cas9 complex, components thereof, nucleic acid molecules, e.g., vectors, involving the same and uses of all of the foregoing, amongst other aspects.

BACKGROUND OF THE INVENTION

Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that employ novel strategies and molecular mechanisms and are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome. This would provide a major resource for new applications in genome engineering and biotechnology.

Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.

SUMMARY OF THE INVENTION

There exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. This invention addresses this need and provides related advantages. The CRISPR/Cas or the CRISPR-Cas system (both terms may be used interchangeably throughout this application) does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. It will be appreciated that reference herein to the Cas protein is restricted to Cas9, including SpCas9, SaCas9 and other orthologs.

Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering and optimization of these genome engineering tools, which are aspects of the claimed invention. In some embodiments, the terms âCRISPR enzymeâ and ânucleic acid-targeting effector proteinâ may be used interchangeably. Indeed, these terms and âeffector proteinâ may also be used interchangeably. The terms âCRISPR Casâ or âCRISPR Cas systemâ andânucleic acid-targeting systemâ may be used interchangeably. The terms âCRISPR complexâ and ânucleic acid-targeting complexâ be used interchangeably. Where reference is made herein to a âtarget locus,â for example a target locus of interest, then it will be appreciated that this may be used interchangeably with the phrase âsequences associated with or at a target locus of interest.â

In one aspect, the invention provides a non-naturally occurring or engineered CRISPR enzyme associated with at least one destabilization domain (DD); and, for shorthand purposes, such a non-naturally occurring or engineered CRISPR enzyme associated with at least one destabilization domain (DD) is herein termed a âDD-CRISPR enzymeâ. In one aspect, the invention provides an engineered, non-naturally occurring DD-CRISPR-Cas system comprising a DD-CRISPR enzyme, wherein the CRISPR enzyme is a Cas9 protein (herein termed a âDD-Cas9 proteinâ, i.e., âDDâ before a term such as âDD-CRISPR-Cas9 complexâ means a CRISPR-Cas9 complex having a Cas9 protein having at least one destabilization domain associated therewith), advantageously a type II DD-Cas9 protein, i.e., a Cas9 protein associated with at least one destabilization domain (herein termed a âDD-Cas9 proteinâ) and guide RNA that targets a nucleic acid molecule such as a DNA molecule, whereby the guide RNA targets the nucleic acid molecule, e.g., DNA molecule. The nucleic acid molecule, e.g., DNA molecule can encode a gene product. In some embodiments the DD-Cas9 protein may cleave the DNA molecule encoding the gene product. In some embodiments expression of the gene product is altered. The Cas9 protein and the guide RNA do not naturally occur together. The invention comprehends the guide RNA comprising a guide sequence fused to a tracr sequence. The invention further comprehends coding for the Cas9 protein being codon optimized for expression in a eukaryotic cell. In a preferred embodiment the eukaryotic cell is a mammalian cell and in a more preferred embodiment the mammalian cell is a human cell. Expression of the gene product may be decreased. The CRISPR enzyme may form part of a CRISPR-Cas9 system, which further comprises a guide RNA (sgRNA) comprising a guide sequence capable of hybridizing to a target sequence in a genomic locus of interest in a cell. In some embodiments, the functional CRISPR-Cas9 system binds to the target sequence. In some embodiments, the functional CRISPR-Ca9s system may edit the target sequence, e.g., the target sequence may comprise a genomic locus, and in some embodiments there may be an alteration of gene expression. In some embodiments, the functional CRISPR-Cas9 system may comprise further functional domains. In some embodiments, the invention provides a method for altering or modifying expression of a gene product. The method may comprise introducing into a cell containing a target nucleic acid, e.g., DNA molecule, or containing and expressing a target nucleic acid, e.g., DNA molecule; for instance, the target nucleic acid may encode a gene product or provide for expression of a gene product (e.g., a regulatory sequence).

The DD-CRISPR enzyme is a DD-Cas9. In some embodiments, the DD-CRISPR enzyme is an Sp DD-Cas9. In some embodiments, the CRISPR enzyme is an Sa DD-Cas9. In some embodiments, the CRISPR enzyme is an St or Fn DD-Cas9, although other orthologs are envisaged. Sp and Sa DD-Cas9s are particularly preferred, in some embodiments. In some embodiments, the DD-CRISPR enzyme cleave both strands of DNA to produce a double strand break (DSB). In some embodiments, the DD-CRISPR enzyme is a nickase. In some embodiments, the DD-CRISPR enzyme is a dual nickase. In some embodiments, the DD-CRISPR enzyme is a deadCas9, e.g., a Cas9 having substantially no nuclease activity, e.g., no more than 5% nuclease activity as compared with a wild-type Cas9 or Cas9 not having had mutations to it.

In some general embodiments, the DD-CRISPR enzyme is associated with one or more functional domains. In some more specific embodiments, the DD-CRISPR enzyme is a deadCas9 and/or is associated with one or more functional domains.

In some embodiments, the DD-CRISPR enzyme comprises a Rec2 or HD2 truncation. In some embodiments, the CRISPR enzyme is associated with the DD by way of a fusion protein. In some embodiments, the CRISPR enzyme is fused to the DD. In other words, the DD may be associated with the CRISPR enzyme by fusion with said CRISPR enzyme. In some embodiments, the enzyme may be considered to be a modified CRISPR enzyme, wherein the CRISPR enzyme is fused to at least one destabilization domain (DD). In some embodiments, the DD may be associated to the CRISPR enzyme via a connector protein, for example using a system such as a marker system such as the streptavidin-biotin system. As such, provided is a fusion of a CRISPR enzyme with a connector protein specific for a high affinity ligand for that connector, whereas the DD is bound to said high affinity ligand. For example, streptavidin may be the connector fused to the CRISPR enzyme, while biotin may be bound to the DD. Upon co-localization, the streptavidin will bind to the biotin, thus connecting the CRISPR enzyme to the DD. For simplicity, a fusion of the CRISPR enzyme and the DD is preferred in some embodiments. In some embodiments, the fusion may be to the N-terminal end of the CRISPR enzyme. In some embodiments, at least one DD is fused to the N-terminus of the CRISPR enzyme. In some embodiments, the fusion may be to the C-terminal end of the CRISPR enzyme. In some embodiments, at least one DD is fused to the C-terminus of the CRISPR enzyme. In some embodiments, one DD may be fused to the N-terminal end of the CRISPR enzyme with another DD fused to the C-terminal of the CRISPR enzyme. In some embodiments, the CRISPR enzyme is associated with at least two DDs and wherein a first DD is fused to the N-terminus of the CRISPR enzyme and a second DD is fused to the C-terminus of the CRISPR enzyme, the first and second DDs being the same or different. In some embodiments, the fusion may be to the N-terminal end of the DD. In some embodiments, the fusion may be to the C-terminal end of the DD. In some embodiments, the fusion may between the C-terminal end of the CRISPR enzyme and the N-terminal end of the DD. In some embodiments, the fusion may between the C-terminal end of the DD and N-terminal end of the CRISPR enzyme. Less background was observed with a DD comprising at least one N-terminal fusion than a DD comprising at least one C terminal fusion. Combining N- and C-terminal fusions had the least background but lowest overall activity. Advantageously a DD is provided through at least one N-terminal fusion or at least one N terminal fusion plus at least one C-terminal fusion. And of course, a DD can be provided by at least one C-terminal fusion.

In some embodiments, the DD is ER50. A corresponding stabilizing ligand for this DD is, in some embodiments, 4HT. As such, in some embodiments, one of the at least one DDs is ER50 and a stabilizing ligand therefor is 4HT or CMP8 In some embodiments, the DD is DHFR50. A corresponding stabilizing ligand for this DD is, in some embodiments, TMP. As such, in some embodiments, one of the at least one DDs is DHFR50 and a stabilizing ligand therefor is TMP. In some embodiments, the DD is ER50. A corresponding stabilizing ligand for this DD is, in some embodiments, CMP8. CMP8 may therefore be an alternative stabilizing ligand to 4HT in the ER50 system. While it may be possible that CMP8 and 4HT can/should be used in a competitive matter, some cell types may be more susceptible to one or the other of these two ligands, and from this disclosure and the knowledge in the art the skilled person can use CMP8 and/or 4HT.

In some embodiments, one or two DDs may be fused to the N-terminal end of the CRISPR enzyme with one or two DDs fused to the C-terminal of the CRISPR enzyme. In some embodiments, the at least two DDs are associated with the CRISPR enzyme and the DDs are the same DD, i.e. the DDs are homologous. Thus, both (or two or more) of the DDs could be ER50 DDs. This is preferred in some embodiments. Alternatively, both (or two or more) of the DDs could be DHFR50 DDs. This is also preferred in some embodiments. In some embodiments, the at least two DDs are associated with the CRISPR enzyme and the DDs are different DDs, i.e. the DDs are heterologous. Thus, one of the DDS could be ER50 while one or more of the or any other DDs could be DHFR50. Having two or more DDs which are heterologous may be advantageous as it would provide a greater level of degradation control. A tandem fusion of more than one DD at the N or C-term may enhance degradation; and such a tandem fusion can be, for example ER50-ER50-Cas9 or DHFR-DHFR-Ca9 It is envisaged that high levels of degradation would occur in the absence of either stabilizing ligand, intermediate levels of degradation would occur in the absence of one stabilizing ligand and the presence of the other (or another) stabilizing ligand, while low levels of degradation would occur in the presence of both (or two of more) of the stabilizing ligands. Control may also be imparted by having an N-terminal ER50 DD and a C-terminal DHFR50 DD.

In some embodiments, the fusion of the CRISPR enzyme with the DD comprises a linker between the DD and the CRISPR enzyme. In some embodiments, the linker is a GlySer linker. In some embodiments, the DD-CRISPR enzyme further comprises at least one Nuclear Export Signal (NES). In some embodiments, the DD-CRISPR enzyme comprises two or more NESs. In some embodiments, the DD-CRISPR enzyme comprises at least one Nuclear Localization Signal (NLS). This may be in addition to an NES. In some embodiments, the CRISPR enzyme comprises or consists essentially of or consists of a localization (nuclear import or export) signal as, or as part of, the linker between the CRISPR enzyme and the DD. HA or Flag tags are also within the ambit of the invention as linkers. Applicants use NLS and/or NES as linker and also use Glycine Serine linkers as short as GS up to (GGGGS) 3 (SEQ ID NO: 27). As shown in the Examples, more than one linker may be used and these may frame a DD on either side (i.e. both Nâ an Câ terminal ends).

In an aspect, the present invention provides a polynucleotide encoding the CRISPR enzyme and associated DD. In some embodiments, the encoded CRISPR enzyme and associated DD are operably linked to a first regulatory element. In some embodiments, a DD is also encoded and is operably linked to a second regulatory element. Advantageously, the DD here is to âmop upâ the stabilizing ligand and so it is advantageously the same DD (i.e. the same type of Domain) as that associated with the enzyme, e.g., as herein discussed (with it understood that the term âmop upâ is meant as discussed herein and may also convey performing so as to contribute or conclude activity). In some embodiments, the first regulatory element is a promoter and may optionally include an enhancer. In some embodiments, the second regulatory element is a promoter and may optionally include an enhancer. In some embodiments, the first regulatory element is an early promoter. In some embodiments, the second regulatory element is a late promoter. In some embodiments, the second regulatory element is or comprises or consists essentially of an inducible control element, optionally the tet system, or a repressible control element, optionally the tetr system. An inducible promoter may be favorable e.g. rTTA to induce tet in the presence of doxycycline.

In an aspect, the present invention provides a means for delivering the

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grant nos. MH100706 and MI 10049 awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

FIELD OF THE INVENTION

BACKGROUND OF THE INVENTION

Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.

SUMMARY OF THE INVENTION

In an aspect, the present invention provides a means for delivering the DD-CRISPR-Cas9 complex of the invention or polynucleotides discussed herein, e.g., particle(s) delivering component(s) of the complex, vector(s) comprising the polynucleotide(s) discussed herein (e.g., encoding the CRISPR enzyme, the DD; providing RNA of the CRISPR-Cas9 complex). In some embodiments, the vector may be a plasmid or a viral vector such as AAV, or lentivirus. Transient transfection with plasmids, e.g., into HEK cells may be advantageous, especially given the size limitations of AAV and that while SpCas9 fits into AAV, one may reach an upper limit with additional coding as to the association with the DD(s).

Also provided is a model that constitutively expresses the CRISPR enzyme and associated DD. The organism may be a transgenic and may have been transfected the present vectors or may be the offspring of an organism so transfected. In a further aspect, the present invention provides compositions comprising the CRISPR enzyme and associated DD or the polynucleotides or vectors described herein. Also provided are CRISPR-Cas9 systems comprising guide RNAs.

Also provided is a method of treating a subject, e.g., a subject in need thereof, comprising inducing gene editing by transforming the subject with the polynucleotide encoding the system or any of the present vectors and administering stabilizing ligand to the subject. A suitable repair template may also be provided, for example delivered by a vector comprising said repair template. Also provided is a method of treating a subject, e.g., a subject in need thereof, comprising inducing transcriptional activation or repression by transforming the subject with the polynucleotide encoding the present system or any of the present vectors, wherein said polynucleotide or vector encodes or comprises the catalytically inactive CRISPR enzyme and one or more associated functional domains; the method further comprising administering a stabilizing ligand to the subject. These methods may also include delivering and/or expressing excess DD to the subject. Where any treatment is occurring ex vivo, for example in a cell culture, then it will be appreciated that the term âsubjectâ may be replaced by the phrase âcell or cell culture.â

Compositions comprising the present system for use in said method of treatment are also provided. A separate composition may comprise the stabilizing ligand. A kit of parts may be provided including such compositions. Use of the present system in the manufacture of a medicament for such methods of treatment are also provided. Use of the present system in screening is also provided by the present invention, e.g., gain of function screens. Cells which are artificially forced to overexpress a gene are be able to down regulate the gene over time (re-establishing equilibrium) e.g. by negative feedback loops. By the time the screen starts the unregulated gene might be reduced again. Using an inducible Cas9 activator allows one to induce transcription right before the screen and therefore minimizes the chance of false negative hits. Accordingly, by use of the instant invention in screening, e.g., gain of function screens, the chance of false negative results may be minimized.

In one aspect, the invention provides an engineered, non-naturally occurring CRISPR-Cas9 system comprising a DD-Cas9 protein and a guide RNA that targets a DNA molecule encoding a gene product in a cell, whereby the guide RNA targets the DNA molecule encoding the gene product and the Cas9 protein cleaves the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas9 protein and the guide RNA do not naturally occur together. The invention comprehends the guide RNA comprising a guide sequence fused to a tracr sequence. In an embodiment of the invention the Cas9 protein is a type II CRISPR-Cas9 protein and is a Cas9 protein. The invention further comprehends coding for the Cas9 protein being codon optimized for expression in a eukaryotic cell. In a preferred embodiment the eukaryotic cell is a mammalian cell and in a more preferred embodiment the mammalian cell is a human cell. In a further embodiment of the invention, the expression of the gene product is decreased.

In another aspect, the invention provides an engineered, non-naturally occurring vector system comprising one or more vectors comprising a first regulatory element operably linked to a CRISPR-Cas9 system guide RNA that targets a DNA molecule encoding a gene product and a second regulatory element operably linked coding for a DD-Cas protein. Components (a) and (b) may be located on same or different vectors of the system. The guide RNA targets the DNA molecule encoding the gene product in a cell and the DD-Cas9 protein may cleaves the DNA molecule encoding the gene product (it may cleave one or both strands or have substantially no nuclease activity), whereby expression of the gene product is altered; and, wherein the DD-Cas9 protein and the guide RNA do not naturally occur together. The invention comprehends the guide RNA comprising a guide sequence fused to a tracr sequence. In an embodiment of the invention the DD-Cas9 protein is a type II DD-CRISPR-Cas9 protein and is a DD-Cas9 protein. The invention further comprehends coding for the DD-Cas9 protein being codon optimized for expression in a eukaryotic cell. In a preferred embodiment the eukaryotic cell is a mammalian cell and in a more preferred embodiment the mammalian cell is a human cell. In a further embodiment of the invention, the expression of the gene product is decreased.

In one aspect, the invention provides a vector system comprising one or more vectors. In some embodiments, the system comprises: (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a DD-CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a DD-CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said DD-CRISPR enzyme comprising at least one nuclear localization sequence and/or at least one NES; wherein components (a) and (b) are located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a DD-CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system comprises the tracr sequence under the control of a third regulatory element, such as a polymerase III promoter. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. Determining optimal alignment is within the purview of one of skill in the art. For example, there are publically and commercially available alignment algorithms and programs such as, but not limited to, ClustalW, Smith-Waterman in matlab, Bowtie, Geneious, Biopython and SeqMan. In some embodiments, the DD-CRISPR complex comprises one or more nuclear localization sequences and/or one or more NES of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in or out of the nucleus of a eukaryotic cell. Without wishing to be bound by theory, it is believed that a nuclear localization sequence and/or NES is not necessary for DD-CRISPR complex activity in eukaryotes, but that including such sequences enhances activity of the system, especially as to targeting nucleic acid molecules in the nucleus and/or having molecules exit the nucleus. In some embodiments, the DD-CRISPR enzyme is a type II DD-CRISPR system enzyme andis a DD-Cas9 enzyme. In some embodiments, the DD-Cas9 enzyme is derived from S. pneumoniae, S. pyogenes, S. thermophiles, F. novicida or S. aureus Cas9 (e.g., a Cas9 of one of these organisms modified to have or be associated with at least one DD), and may include further mutations or alterations or be a chimeric Cas9. The enzyme may be a DD-Cas9 homolog or ortholog. In some embodiments, the DD-CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the DD-CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In general, and throughout this specification, the term âvectorâ refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single-stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g., circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a âplasmid,â which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g., retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses). Viral vectors also include polynucleotides carried by a virus for transfection into a host cell. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as âexpression vectors.â Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, âoperably linkedâ is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term âregulatory elementâ is intended to include promoters, enhancers, internal ribosomal entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g., liver, pancreas), or particular cell types (e.g., lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In some embodiments, a vector comprises one or more pol III promoter (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the 3-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EFla promoter. Also encompassed by the term âregulatory elementâ are enhancer elements, such as WPRE; CMV enhancers; the R-U5â² segment in LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit Î²-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRISPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).

Advantageous vectors include lentiviruses and adeno-associated viruses, and types of such vectors can also be selected for targeting particular types of cells.

In one aspect, the invention provides a vector comprising a regulatory element operably linked to an enzyme-coding sequence encoding a DD-CRISPR enzyme comprising one or more nuclear localization sequences and/or NES. In some embodiments, said regulatory element drives transcription of the DD-CRISPR enzyme in a eukaryotic cell such that said DD-CRISPR enzyme accumulates in a detectable amount in the nucleus of the eukaryotic cell and/or is exported from the nucleus. In some embodiments, the regulatory element is a polymerase II promoter. In some embodiments, the DD-CRISPR enzyme is a type II DD-CRISPR system enzyme and is a DD-Cas9 enzyme. In some embodiments, the DD-Cas9 enzyme is derived from S. pneumoniae, S. pyogenes, S. thermophilus, F. novicida or S. aureus Cas9 (e.g., modified to have or be associated with at least one DD), and may include further alteration or mutation of the Cas9, and can be a chimeric Cas9. In some embodiments, the DD-CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the DD-CRISPR enzyme lacks or substantially DNA strand cleavage activity (e.g., no more than 5% nuclease activity as compared with a wild type enzyme or enzyme not having the mutation or alteration that decreases nuclease activity).

In one aspect, the invention provides a DD-CRISPR enzyme comprising one or more nuclear localization sequences and/or NES of sufficient strength to drive accumulation of said DD-CRISPR enzyme in a detectable amount in and/or out of the nucleus of a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme is a type II DD-CRISPR system enzyme and is a DD-Cas9 enzyme. In some embodiments, the DD-Cas9 enzyme is derived from S. pneumoniae, S. pyogenes, S. thermophilus, F. novicida or S. aureus Cas9 (e.g., modified to have or be associated with at least one DD), and may include further alteration or mutation of the Cas9, and can be a chimeric Cas9. In some embodiments, the DD-CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the DD-CRISPR enzyme lacks or substantially DNA strand cleavage activity (e.g., no more than 5% nuclease activity as compared with a wild type enzyme or enzyme not having the mutation or alteration that decreases nuclease activity).

In one aspect, the invention provides a eukaryotic host cell comprising (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a DD-CRISPR complex to a target sequence in a eukaryotic cell, wherein the DD-CRISPR complex comprises a DD-CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said DD-CRISPR enzyme comprising at least one nuclear localization sequence and/or NES. In some embodiments, the host cell comprises components (a) and (b). In some embodiments, component (a), component (b), or components (a) and (b) are stably integrated into a genome of the host eukaryotic cell. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a DD-CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the eukaryotic host cell further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the DD-CRISPR enzyme comprises one or more nuclear localization sequences and/or nuclear export sequences or NES of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in and/or out of the nucleus of a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme is a type II CRISPR system enzyme and is a Cas9 enzyme. In some embodiments, the DD-Cas9 enzyme is derived from S. pneumoniae, S. pyogenes, S. thermophilus, F. novicida or S. aureus Cas9 (e.g., modified to have or be associated with at least one DD), and may include further alteration or mutation of the Cas9, and can be a chimeric Cas9. In some embodiments, the DD-CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the DD-CRISPR enzyme lacks or substantially DNA strand cleavage activity (e.g., no more than 5% nuclease activity as compared with a wild type enzyme or enzyme not having the mutation or alteration that decreases nuclease activity). In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length. In an aspect, the invention provides a non-human eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. In other aspects, the invention provides a eukaryotic organism; preferably a multicellular eukaryotic organism, comprising a eukaryotic host cell according to any of the described embodiments. The organism in some embodiments of these aspects may be an animal; for example a mammal such as a mouse. Also, the organism may be an arthropod such as an insect, for instance, a fly (especially fruit flies including model organisms such as Drosophila melanogaster as well as agricultural pests such as olive fly) or a mosquito. Indeed, insect and arthropod models, disease vectors and pests are preferred, including moths, mosquitoes, boring insects, fruit flies etc. The organism may be a nematode such as C. elegans . The organism also may be a plant. Further, the organism may be a fungus.

With respect to use of the CRISPR-Cas system generally, mention is made of the documents, including patent applications, patents, and patent publications cited throughout this disclosure as embodiments of the invention can be used as in those documents. CRISPR-Cas system(s) (e.g., single or multiplexed) can be used in conjunction with recent advances in crop genomics. Such CRISPR-Cas system(s) can be used to perform efficient and cost effective plant gene or genome interrogation or editing or manipulationâfor instance, for rapid investigation and/or selection and/or interrogations and/or comparison and/or manipulations and/or transformation of plant genes or genomes; e.g., to create, identify, develop, optimize, or confer trait(s) or characteristic(s) to plant(s) or to transform a plant genome. There can accordingly be improved production of plants, new plants with new combinations of traits or characteristics or new plants with enhanced traits. Such CRISPR-Cas system(s) can be used with regard to plants in Site-Directed Integration (SDI) or Gene Editing (GE) or any Near Reverse Breeding (NRB) or Reverse Breeding (RB) techniques. With respect to use of the CRISPR-Cas system in plants, mention is made of the University of Arizona website âCRISPR-PLANTâ (www.genome.arizona.edu/crispr/) (supported by Penn State and AGI). Embodiments of the invention can be used in genome editing in plants or where RNAi or similar genome editing techniques have been used previously; see, e.g., Nekrasov, âPlant genome editing made easy: targeted mutagenesis in model and crop plants using the CRISPR/Cas system,â Plant Methods 2013, 9:39 (doi:10.1186/1746-4811-9-39); Brooks, âEfficient gene editing in tomato in the first generation using the CRISPR/Cas9 system,â Plant Physiology September 2014 pp 114.247577; Shan, âTargeted genome modification of crop plants using a CRISPR-Cas system,â Nature Biotechnology 31, 686-688 (2013); Feng, âEfficient genome editing in plants using a CRISPR/Cas system,â Cell Research (2013) 23:1229-1232. doi:10.1038/cr.2013.114; published online 20 Aug. 2013; Xie, âRNA-guided genome editing in plants using a CRISPR-Cas system,â Mol Plant. 2013 November; 6(6):1975-83. doi: 10.1093/mp/sst119. Epub 2013 Aug 17; Xu, âGene targeting using the Agrobacterium tumefaciens -mediated CRISPR-Cas system in rice,â Rice 2014, 7:5 (2014), Zhou et al., âExploiting SNPs for biallelic CRISPR mutations in the outcrossing woody perennial Populus reveals 4-coumarate: CoA ligase specificity and Redundancy,â New Phytologist (2015) (Forum) 1-4 (available online only at www.newphytologist.com); Caliando et al, âTargeted DNA degradation using a CRISPR device stably carried in the host genome, NATURE COMMUNICATIONS 6:6989, DOI: 10.1038/ncomms7989, worldwideweb.nature.com/naturecommunications DOI: 10.1038/ncomms7989; U.S. Pat. No. 6,603,061 âAgrobacterium -Mediated Plant Transformation Method; U.S. Pat. No. 7,868,149âPlant Genome Sequences and Uses Thereof and US 2009/0100536âTransgenic Plants with Enhanced Agronomic Traits, all the contents and disclosure of each of which are herein incorporated by reference in their entirety. In the practice of the invention, the contents and disclosure of Morrell et al âCrop genomics: advances and applications,â Nat Rev Genet. 2011 Dec. 29; 13(2):85-96; each of which is incorporated by reference herein including as to how herein embodiments may be used as to plants. Accordingly, reference herein to animal cells may also apply, mutatis mutandis, to plant cells unless otherwise apparent.

In one aspect, the invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for using the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, wherein when expressed, the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, wherein the CRISPR complex comprises a CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and/or (b) a second regulatory element operably linked to an enzyme-coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the kit comprises components (a) and (b) located on the same or different vectors of the system. In some embodiments, component (a) further comprises the tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, wherein when expressed, each of the two or more guide sequences direct sequence specific binding of a CRISPR complex to a different target sequence in a eukaryotic cell. In some embodiments, the system further comprises a third regulatory element, such as a polymerase III promoter, operably linked to said tracr sequence. In some embodiments, the tracr sequence exhibits at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR enzyme in a detectable amount in the nucleus of a eukaryotic cell. The CRISPR enzyme is a type II CRISPR system enzyme and is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is derived from S. pneumoniae, S. pyogenes, S. thermophilus, F. novicida or S. aureus Cas9 (e.g., modified to have or be associated with at least one DD), and may include further alteration or mutation of the Cas9, and can be a chimeric Cas9. In some embodiments, the DD-CRISPR enzyme is codon-optimized for expression in a eukaryotic cell. In some embodiments, the DD-CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the DD-CRISPR enzyme lacks or substantially DNA strand cleavage activity (e.g., no more than 5% nuclease activity as compared with a wild type enzyme or enzyme not having the mutation or alteration that decreases nuclease activity). In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or between 10-30, or between 15-25, or between 15-20 nucleotides in length.

In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a DD-CRISPR complex to bind to the target polynucleotide, e.g., to effect cleavage of said target polynucleotide, thereby modifying the target polynucleotide, wherein the DD-CRISPR complex comprises a DD-CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said DD-CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the DD-CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in a subject. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from a subject prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said subject.

In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a DD-CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the DD-CRISPR complex comprises a DD-CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the DD-CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.

In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a DD-CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a DD-CRISPR complex to bind to a target polynucleotide, e.g., to effect cleavage of the target polynucleotide within said disease gene, wherein the DD-CRISPR complex comprises the DD-CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said DD-CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.

In one aspect, the invention provides a method for developing a biologically active agent that modulates a cell signaling event associated with a disease gene. In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) contacting a test compound with a model cell of any one of the described embodiments; and (b) detecting a change in a readout that is indicative of a reduction or an augmentation of a cell signaling event associated with said mutation in said disease gene, thereby developing said biologically active agent that modulates said cell signaling event associated with said disease gene.

In one aspect, the invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence when expressed directs sequence-specific binding of a DD-CRISPR complex to a corresponding target sequence present in a eukaryotic cell. In some embodiments, the target sequence is a viral sequence present in a eukaryotic cell. In some embodiments, the target sequence is a proto-oncogene or an oncogene.

In one aspect the invention provides for a method of selecting one or more cell(s) by introducing one or more mutations in a gene in the one or more cell (s), the method comprising: introducing one or more vectors into the cell (s), wherein the one or more vectors drive expression of one or more of: a DD-CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and an editing template; wherein the editing template comprises the one or more mutations that abolish DD-CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the cell(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the DD-CRISPR complex comprises the DD-CRISPR enzyme complexed with (1) the guide sequence that is hybridized to the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the DD-CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more cell(s) in which one or more mutations have been introduced to be selected. The DD-CRISPR enzyme is DD-Cas9. In another aspect of the invention the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system. The cell(s) may be prokaryotic or eukaryotic cells.

With respect to mutations of the DD-CRISPR enzyme, when the enzyme is not SpCas9, mutations may be made at any or all residues corresponding to positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 (which may be ascertained for instance by standard sequence comparison tools). In particular, any or all of the following mutations are preferred in SpCas9: D10A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged. In an aspect the invention provides as to any or each or all embodiments herein-discussed wherein the DD-CRISPR enzyme comprises at least one or more, or at least two or more mutations, wherein the at least one or more mutation or the at least two or more mutations is as to D10, E762, H840, N854, N863, or D986 according to SpCas9 protein, e.g., D10A, E762A, H840A, N854A, N863A and/or D986A as to SpCas9, or N580 according to SaCas9, e.g., N580A as to SaCas9, or any corresponding mutation(s) in a Cas9 of an ortholog to Sp or Sa, or the CRISPR enzyme comprises at least one mutation wherein at least H840 or N863A as to Sp Cas9 or N580A as to Sa Cas9 is mutated; e.g., wherein the CRISPR enzyme comprises H840A, or D10A and H840A, or D10A and N863A, according to SpCas9 protein, or any corresponding mutation(s) in a Cas9 of an ortholog to Sp protein or Sa protein.

In a further aspect, the invention involves a computer-assisted method for identifying or designing potential compounds to fit within or bind to DD-CRISPR-Cas9 system or a functional portion thereof or vice versa (a computer-assisted method for identifying or designing potential DD-CRISPR-Cas9 systems or a functional portion thereof for binding to desired compounds) or a computer-assisted method for identifying or designing potential DD-CRISPR-Cas9 systems (e.g., with regard to predicting areas of the DD-CRISPR-Cas9 system to be able to be manipulatedâfor instance, based on crystal structure data or based on data of Cas9 orthologs, or with respect to where a functional group such as an activator or repressor can be attached to the DD-CRISPR-Cas9 system, or as to Cas9 truncations or as to designing nickases), said method comprising: using a computer system, e.g., a programmed computer comprising a processor, a data storage system, an input device, and an output device, the steps of: (a) inputting into the programmed computer through said input device data comprising the three-dimensional co-ordinates of a subset of the atoms from or pertaining to the DD-CRISPR-Cas9 crystal structure, e.g., in the DD-CRISPR-Cas9 system binding domain or alternatively or a

CLAIMS

Claims ( 20 )

1 . (canceled)

2 . A method for modifying a eukaryotic cell, comprising:

contacting the eukaryotic cell with a stabilizing ligand, wherein the eukaryotic cell comprises a CRISPR-Cas system comprising (a) an engineered Cas9 protein fused to at least one destabilization domain, and (b) a CRISPR-Cas system chimeric RNA capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in the eukaryotic cell; wherein the stabilizing ligand binds to the destabilization domain, thereby inhibiting degradation of the Cas9 protein by proteasome, wherein the chimeric RNA forms a CRISPR complex with the Cas9 protein and directs sequence-specific binding of the CRISPR complex to the target sequence.

3 . The method of claim 2 , wherein the Cas9 protein is S. pyogenes Cas9.

4 . The method of claim 2 , wherein the Cas9 protein is S. aureus Cas9.

5 . The method of claim 2 , wherein the Cas9 protein is fused to at least two destabilization domains.

6 . The method of claim 2 , wherein the Cas9 protein is fused to at least one destabilization domain at the N-terminus and at least one destabilization domain at the C-terminus.

7 . The method of claim 2 , wherein the destabilization domain comprises a DHFR50 domain.

8 . The method of claim 7 , wherein the stabilizing ligand comprises trimethoprim (TMP).

9 . The method of claim 2 , wherein the destabilization domain comprises an ER50 domain.

10 . The method of claim 9 , wherein the stabilizing ligand comprises 4-hydroxytamoxifen (4HT) or CMP8.

11 . The method of claim 7 , wherein the Cas9 protein is fused to a first DHFR domain at the N-terminus and a second DHFR domain at the C-terminus.

12 . The method of claim 7 , wherein the DHFR domain comprises the amino acid sequence set forth in SEQ ID NO: 50 or SEQ ID NO:51.

13 . The method of claim 9 , wherein the Cas9 protein is fused to a first ER50 domain at the N-terminus and a second ER50 domain at the C-terminus.

14 . The method of claim 9 , wherein the ER50 domain comprises the amino acid sequence set forth in SEQ ID NO: 52.

15 . The method of claim 2 , wherein the Cas9 protein comprises at least one mutation in at least one catalytic domain and is fused to at least one heterologous protein domain.

16 . The method of claim 15 , wherein the Cas9 protein is S. pyogenes Cas9 and the at least one mutation comprises D10A, H840A, or both.

17 . The method of claim 15 , wherein the Cas9 protein is S. aureus Cas9 and the at least one mutation comprises D10A, N580A, or both.

18 . The method of claim 15 , wherein the heterologous protein domain is selected from the group consisting of epitope tags, reporter sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, or nucleic acid binding activity.

19 . The method of claim 2 , wherein the eukaryotic cell is a mammalian cell or a human cell.

20 . A method for modifying a eukaryotic cell, comprising:

administrating a CRISPR-Cas system to the eukaryotic cell, wherein the CRISPR-Cas system comprising (a) an engineered Cas9 protein fused to at least one destabilization domain, and (b) a CRISPR-Cas system chimeric RNA capable of hybridizing to a target sequence adjacent to a protospacer adjacent motif (PAM) in the eukaryotic cell; and administrating a stabilizing ligand to the eukaryotic cell, wherein the stabilizing ligand binds to the destabilization domain, thereby inhibiting degradation of the Cas9 protein by proteasome, wherein the chimeric RNA forms a CRISPR complex with the Cas9 protein and directs sequence-specific binding of the CRISPR complex to the target sequence.

US19/345,111

2014-12-24

2025-09-30

Crispr having or associated with destabilization domains

Pending

US20260152731A1

( en )

Priority Applications (1)

Application Number

Priority Date

Filing Date

Title

US19/345,111

US20260152731A1

( en )

2014-12-24

2025-09-30

Crispr having or associated with destabilization domains

Applications Claiming Priority (6)

Application Number

Priority Date

Filing Date

Title

US201462096656P

2014-12-24

US201562181151P

2015-06-17

PCT/US2015/067177

WO2016106244A1

( en )

2014-12-24

2015-12-21

Crispr having or associated with destabilization domains

US15/633,126

US20170306307A1

( en )

2014-12-24

2017-06-26

Crispr having or associated with destabilization domains

US17/081,387

US12435320B2

( en )

2014-12-24

2020-10-27

CRISPR having or associated with destabilization domains

US19/345,111

US20260152731A1

( en )

2014-12-24

2025-09-30

Crispr having or associated with destabilization domains

Related Parent Applications (1)

Application Number

Title

Priority Date

Filing Date

US17/081,387

Continuation

US12435320B2

( en )

2014-12-24

2020-10-27

CRISPR having or associated with destabilization domains

Publications (1)

Publication Number

Publication Date

US20260152731A1

true

US20260152731A1 ( en )

2026-06-04

Family

ID=55273518

Family Applications (3)

Application Number

Title

Priority Date

Filing Date

US15/633,126

Abandoned

US20170306307A1

( en )

2014-12-24

2017-06-26

Crispr having or associated with destabilization domains

US17/081,387

Active

2039-07-14

US12435320B2

( en )

2014-12-24

2020-10-27

CRISPR having or associated with destabilization domains

US19/345,111

Pending

US20260152731A1

( en )

2014-12-24

2025-09-30

Crispr having or associated with destabilization domains

Family Applications Before (2)

Application Number

Title

Priority Date

Filing Date

US15/633,126

Abandoned

US20170306307A1

( en )

2014-12-24

2017-06-26

Crispr having or associated with destabilization domains

US17/081,387

Active

2039-07-14

US12435320B2

( en )

2014-12-24

2020-10-27

CRISPR having or associated with destabilization domains

Country Status (5)

Country

Link

( 3 )

US20170306307A1

( en )

( 2 )

EP3237615B2

( en )

( 1 )

AU2015369725A1

( en )

( 1 )

CA2970370A1

( en )

( 1 )

WO2016106244A1

( en )

Families Citing this family (123)

* Cited by examiner, â Cited by third party

Publication number

Priority date

Publication date

Assignee

Title

WO2013066438A2

( en )

2011-07-22

2013-05-10

President And Fellows Of Harvard College

Evaluation and improvement of nuclease cleavage specificity

US9163284B2

( en )

2013-08-09

2015-10-20

President And Fellows Of Harvard College

Methods for identifying a target site of a Cas9 nuclease

US9359599B2

( en )

2013-08-22

2016-06-07

President And Fellows Of Harvard College

Engineered transcription activator-like effector (TALE) domains and uses thereof

US9322037B2

( en )

2013-09-06

2016-04-26

President And Fellows Of Harvard College

Cas9-FokI fusion proteins and uses thereof

US9340799B2

( en )

2013-09-06

2016-05-17

President And Fellows Of Harvard College

MRNA-sensing switchable gRNAs

US9526784B2

( en )

2013-09-06

2016-12-27

President And Fellows Of Harvard College

Delivery system for functional nucleases

US20150166984A1

( en )

2013-12-12

2015-06-18

President And Fellows Of Harvard College

Methods for correcting alpha-antitrypsin point mutations

AU2015298571B2

( en )

2014-07-30

2020-09-03

President And Fellows Of Harvard College

Cas9 proteins including ligand-dependent inteins

EP3204496A1

( en )

2014-10-10

2017-08-16

Editas Medicine, Inc.

Compositions and methods for promoting homology directed repair

WO2016073990A2

( en )

2014-11-07

2016-05-12

Editas Medicine, Inc.

Methods for improving crispr/cas-mediated genome-editing

CA2986310A1

( en )

2015-05-11

2016-11-17

Editas Medicine, Inc.

Optimized crispr/cas9 systems and methods for gene editing in stem cells

US11911415B2

( en )

2015-06-09

2024-02-27

Editas Medicine, Inc.

CRISPR/Cas-related methods and compositions for improving transplantation

JP2018519811A

( en )

2015-06-29

2018-07-26

Modified CRISPR RNA and modified single CRISPR RNA and uses thereof

CA2999500A1

( en )

2015-09-24

2017-03-30

Editas Medicine, Inc.

Use of exonucleases to improve crispr/cas-mediated genome editing

CN116814590A

( en )

2015-10-22

2023-09-29

å¸ç½å¾·ç ç©¶ææéå¬å¸

VI-B type CRISPR enzyme and system

WO2017070632A2

( en )

2015-10-23

2017-04-27

President And Fellows Of Harvard College

Nucleobase editors and uses thereof

WO2017074962A1

( en )

2015-10-30

2017-05-04

Brandeis University

Modified cas9 compositions and methods of use

SG11201803151PA

( en )

2015-11-05

2018-05-30

Agency Science Tech & Res

Chemical-inducible genome engineering technology

CA3005878A1

( en )

2015-11-19

2017-05-26

The Brigham And Women's Hospital, Inc.

Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity

WO2017106616A1

( en )

2015-12-17

2017-06-22

The Regents Of The University Of Colorado, A Body Corporate

Varicella zoster virus encoding regulatable cas9 nuclease

US11427861B2

( en )

2016-03-17

2022-08-30

Massachusetts Institute Of Technology

Methods for identifying and modulating co-occurant cellular phenotypes

WO2017165826A1

( en )

2016-03-25

2017-09-28

Editas Medicine, Inc.

Genome editing systems comprising repair-modulating enzyme molecules and methods of their use

WO2017180587A2

( en )

2016-04-11

2017-10-19

Obsidian Therapeutics, Inc.

Regulated biocircuit systems

US11236313B2

( en )

2016-04-13

2022-02-01

Editas Medicine, Inc.

Cas9 fusion molecules, gene editing systems, and methods of use thereof

WO2018005873A1

( en )

2016-06-29

2018-01-04

The Broad Institute Inc.

Crispr-cas systems having destabilization domain

SG11201900038QA

( en )

2016-07-05

2019-02-27

Univ Johns Hopkins

Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter

WO2018027078A1

( en )

2016-08-03

2018-02-08

President And Fellows Of Harard College

Adenosine nucleobase editors and uses thereof

AU2017308889B2

( en )

2016-08-09

2023-11-09

President And Fellows Of Harvard College

Programmable Cas9-recombinase fusion proteins and uses thereof

US11352647B2

( en )

2016-08-17

2022-06-07

The Broad Institute, Inc.

Crispr enzymes and systems

WO2018035387A1

( en )

2016-08-17

2018-02-22

The Broad Institute, Inc.

Novel crispr enzymes and systems

WO2018039438A1

( en )

2016-08-24

2018-03-01

President And Fellows Of Harvard College

Incorporation of unnatural amino acids into proteins using base editing

US12499971B2

( en )

2016-09-28

2025-12-16

The Broad Institute, Inc.

Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof

US12447213B2

( en )

2016-10-07

2025-10-21

The Broad Institute, Inc.

Modulation of novel immune checkpoint targets

KR20240007715A

( en )

2016-10-14

2024-01-16

íë ì§ëí¸ ì¤ë í ë¡ì°ì¦ ì¤ë¸ íë°ë ì¹¼ë¦¬ì§

Aav delivery of nucleobase editors

WO2018083606A1

( en )

2016-11-01

2018-05-11

Novartis Ag

Methods and compositions for enhancing gene editing

WO2018089386A1

( en )

2016-11-11

2018-05-17

The Broad Institute, Inc.

Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action

EP3555297A1

( en )

2016-12-19

2019-10-23

Editas Medicine, Inc.

Assessing nuclease cleavage

WO2018119359A1

( en )

2016-12-23

2018-06-28

President And Fellows Of Harvard College

Editing of ccr5 receptor gene to protect against hiv infection

WO2018129368A2

( en )

2017-01-06

2018-07-12

Editas Medicine, Inc.

Methods of assessing nuclease cleavage

TW201839136A

( en )

2017-02-06

2018-11-01

çå£«åè«¾è¯å¬å¸

Composition and method for treating hemochromatosis

KR20190123328A

( en )

2017-03-09

2019-10-31

íë ì§ëí¸ ì¤ë í ë¡ì°ì¦ ì¤ë¸ íë°ë ì¹¼ë¦¬ì§

Cancer vaccine

WO2018165504A1

( en )

2017-03-09

2018-09-13

President And Fellows Of Harvard College

Suppression of pain by gene editing

CN110914310A

( en )

2017-03-10

2020-03-24

åä½å¤§å¦çæ ¡é¿åæåä»¬

Cytosine to guanine base editor

IL306092A

( en )

2017-03-23

2023-11-01

Harvard College

Nucleobase editors comprising nucleic acid programmable dna binding proteins

US12161694B2

( en )

2017-03-24

2024-12-10

The Broad Institute, Inc.

Methods and compositions for regulating innate lymphoid cell inflammatory responses

US11963966B2

( en )

2017-03-31

2024-04-23

Dana-Farber Cancer Institute, Inc.

Compositions and methods for treating ovarian tumors

EP3606518A4

( en )

2017-04-01

2021-04-07

The Broad Institute, Inc.

METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF A GENE SIGNATURE OF RESISTANCE TO IMMUNOTHERAPY IN CANCER

US20200071773A1

( en )

2017-04-12

2020-03-05

Massachusetts Eye And Ear Infirmary

Tumor signature for metastasis, compositions of matter methods of use thereof

WO2018191520A1

( en )

2017-04-12

2018-10-18

The Broad Institute, Inc.

Respiratory and sweat gland ionocytes

US12590288B2

( en )

2017-04-12

2026-03-31

The Broad Institute, Inc.

Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response

WO2018195486A1

( en )

2017-04-21

2018-10-25

The Broad Institute, Inc.

Targeted delivery to beta cells

US11499151B2

( en )

2017-04-28

2022-11-15

Editas Medicine, Inc.

Methods and systems for analyzing guide RNA molecules

US11591601B2

( en )

2017-05-05

2023-02-28

The Broad Institute, Inc.

Methods for identification and modification of lncRNA associated with target genotypes and phenotypes

US12226479B2

( en )

2017-05-11

2025-02-18

The General Hospital Corporation

Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof

US11560566B2

( en )

2017-05-12

2023-01-24

President And Fellows Of Harvard College

Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation

EP3625342B1

( en )

2017-05-18

2022-08-24

The Broad Institute, Inc.

Systems, methods, and compositions for targeted nucleic acid editing

KR102678809B1

( en )

2017-05-18

2024-06-26

ë ë¸ë¡ë ì¸ì¤í°íí¸, ì¸ì½í¼ë ì´í°ë

Systems, methods and compositions for targeted nucleic acid editing

CN110997908A

( en )

2017-06-09

2020-04-10

ç±è¿ªå¡æ¯å»è¯å¬å¸

Engineered CAS9 nucleases

EP3638218A4

( en )

2017-06-14

2021-06-09

The Broad Institute, Inc.

COMPOSITIONS AND METHODS TARGETING COMPONENT 3 OF THE COMPLEMENT TO INHIBIT TUMOR GROWTH

CN111328290A

( en )

2017-06-26

2020-06-23

åå¾·ç ç©¶æ

CRISPR/CAS-adenine deaminase-based compositions, systems, and methods for targeted nucleic acid editing

US20200140896A1

( en )

2017-06-30

2020-05-07

Novartis Ag

Methods for the treatment of disease with gene editing systems

EP3652312A1

( en )

2017-07-14

2020-05-20

Editas Medicine, Inc.

Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites

WO2019014581A1

( en )

2017-07-14

2019-01-17

The Broad Institute, Inc.

Methods and compositions for modulating cytotoxic lymphocyte activity

EP3654993A4

( en )

2017-07-17

2021-08-25

The Broad Institute, Inc.

HUMAN COLON CELL ATLAS IN GOOD HEALTH WITH HEMORRHAGIC RECTO-COLITIS

EP3658573A1

( en )

2017-07-28

2020-06-03

President and Fellows of Harvard College

Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)

AU2018320864B2

( en )

2017-08-22

2024-02-22

Napigen, Inc.

Organelle genome modification using polynucleotide guided endonuclease

EP3676376B1

( en )

2017-08-30

2025-01-15

President and Fellows of Harvard College

High efficiency base editors comprising gam

KR102338449B1

( en )

2017-09-21

2021-12-10

ë ë¸ë¡ë ì¸ì¤í°íí¸, ì¸ì½í¼ë ì´í°ë

Systems, methods, and compositions for targeted nucleic acid editing

CA3111479A1

( en )

2017-09-26

2019-04-04

The Board Of Trustees Of The University Of Illinois

Crispr/cas system and method for genome editing and modulating transcription

WO2019070755A1

( en )

2017-10-02

2019-04-11

The Broad Institute, Inc.

Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer

WO2019071054A1

( en )

2017-10-04

2019-04-11

The Broad Institute, Inc.

Methods and compositions for altering function and structure of chromatin loops and/or domains

CA3082251A1

( en )

2017-10-16

2019-04-25

The Broad Institute, Inc.

Uses of adenosine base editors

SG11202003415XA

( en )

2017-10-18

2020-05-28

Novartis Ag

Compositions and methods for selective protein degradation

US12227742B2

( en )

2017-10-23

2025-02-18

The Broad Institute, Inc.

Nucleic acid modifiers

EP3704245A1

( en )

2017-11-01

2020-09-09

Novartis AG

Synthetic rnas and methods of use

US12171783B2

( en )

2017-11-13

2024-12-24

The Broad Institute, Inc.

Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas

WO2019094984A1

( en )

2017-11-13

2019-05-16

The Broad Institute, Inc.

Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells

JP2021503893A

( en )

2017-11-21

2021-02-15

Gender induction and fertility of insects by endonucleases

EP3714055A1

( en )

2017-11-21

2020-09-30

CRISPR Therapeutics AG

Materials and methods for treatment of autosomal dominant retinitis pigmentosa

US11332736B2

( en )

2017-12-07

2022-05-17

The Broad Institute, Inc.

Methods and compositions for multiplexing single cell and single nuclei sequencing

US12406749B2

( en )

2017-12-15

2025-09-02

The Broad Institute, Inc.

Systems and methods for predicting repair outcomes in genetic engineering

US11994512B2

( en )

2018-01-04

2024-05-28

Massachusetts Institute Of Technology

Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity

CN108694305B

( en )

2018-03-30

2021-06-11

Biological information analysis system based on cloud computing

US11957695B2

( en )

2018-04-26

2024-04-16

The Broad Institute, Inc.

Methods and compositions targeting glucocorticoid signaling for modulating immune responses

US12281301B2

( en )

2018-04-27

2025-04-22

The Broad Institute, Inc.

Sequencing-based proteomics

US20210386829A1

( en )

2018-05-04

2021-12-16

The Broad Institute, Inc.

Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses

WO2019226953A1

( en )

2018-05-23

2019-11-28

The Broad Institute, Inc.

Base editors and uses thereof

WO2019232542A2

( en )

2018-06-01

2019-12-05

Massachusetts Institute Of Technology

Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients

US12036240B2

( en )

2018-06-14

2024-07-16

The Broad Institute, Inc.

Compositions and methods targeting complement component 3 for inhibiting tumor growth

SG11202011240YA

( en )

2018-06-26

2020-12-30

Broad Inst Inc

Crispr/cas and transposase based amplification compositions, systems and methods

CA3102163A1

( en )

2018-06-26

2020-01-02

Massachusetts Institute Of Technology

Crispr effector system based amplification methods, systems, and diagnostics

AU2019291918B2

( en )

2018-06-29

2025-06-12

Editas Medicine, Inc.

Synthetic guide molecules, compositions and methods relating thereto

EP3820495A4

( en )

2018-07-09

2022-07-20

The Broad Institute Inc.

RNA PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES

WO2020041380A1

( en )

2018-08-20

2020-02-27

The Broad Institute, Inc.

Methods and compositions for optochemical control of crispr-cas9

WO2020041387A1

( en )

2018-08-20

2020-02-27

The Brigham And Women's Hospital, Inc.

Degradation domain modifications for spatio-temporal control of rna-guided nucleases

US20210317479A1

( en )

2018-09-06

2021-10-14

The Broad Institute, Inc.

Nucleic acid assemblies for use in targeted delivery

EP3852813A4

( en )

2018-09-18

2022-06-22

VNV Newco Inc.

ARC-BASED CAPSIDS AND THEIR USES

US20210403907A1

( en )

2018-09-18

2021-12-30

Vnv Newco Inc.

Arc-based capsids and uses thereof

WO2020072646A1

( en )

2018-10-04

2020-04-09

Blueallele, Llc

Materials and methods for the correction of retinitis pigmentosa

US20220411783A1

( en )

2018-10-12

2022-12-29

The Broad Institute, Inc.

Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues

WO2020081730A2

( en )

2018-10-16

2020-04-23

Massachusetts Institute Of Technology

Methods and compositions for modulating microenvironment

WO2020092453A1

( en )

2018-10-29

2020-05-07

The Broad Institute, Inc.

Nucleobase editors comprising geocas9 and uses thereof

US12165743B2

( en )

2018-11-09

2024-12-10

The Broad Institute, Inc.

Compressed sensing for screening and tissue imaging

US12402610B2

( en )

2018-11-09

2025-09-02

The Broad Institute, Inc.

Methods and compositions for modulating innate lymphoid cell pathogenic effectors

US12264323B2

( en )

2018-12-17

2025-04-01

The Broad Institute, Inc.

CRISPR CPF1 direct repeat variants

US11739156B2

( en )

2019-01-06

2023-08-29

The Broad Institute, Inc. Massachusetts Institute of Technology

Methods and compositions for overcoming immunosuppression

US12351837B2

( en )

2019-01-23

2025-07-08

The Broad Institute, Inc.

Supernegatively charged proteins and uses thereof

BR112021017744A2

( en )

2019-03-08

2021-11-16

Obsidian Therapeutics Inc

CD40L Compositions and Methods for Adjustable Regulation

US12534714B2

( en )

2019-03-18

2026-01-27

The Broad Institute, Inc.

Type VII CRISPR proteins and systems

WO2020191241A1

( en )

2019-03-19

2020-09-24

The Broad Institute, Inc.

Methods and compositions for editing nucleotide sequences

WO2020214842A1

( en )

2019-04-17

2020-10-22

The Broad Institute, Inc.

Adenine base editors with reduced off-target effects

US20220220469A1

( en )

2019-05-20

2022-07-14

The Broad Institute, Inc.

Non-class i multi-component nucleic acid targeting systems

WO2020243661A1

( en )

2019-05-31

2020-12-03

The Broad Institute, Inc.

Methods for treating metabolic disorders by targeting adcy5

CN110241099B

( en )

2019-06-05

2021-04-30

å¤æ¦å¤§å¦

Truncated variants of the CRISPR nuclease SpCas9 of Streptococcus pyogenes and their applications

US12297426B2

( en )

2019-10-01

2025-05-13

The Broad Institute, Inc.

DNA damage response signature guided rational design of CRISPR-based systems and therapies

US11981922B2

( en )

2019-10-03

2024-05-14

Dana-Farber Cancer Institute, Inc.

Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment

US12435330B2

( en )

2019-10-10

2025-10-07

The Broad Institute, Inc.

Methods and compositions for prime editing RNA

AU2021205416B2

( en )

2020-01-08

2026-08-06

Obsidian Therapeutics, Inc.

Compositions and methods for tunable regulation of transcription

US20230340537A1

( en )

2020-01-17

2023-10-26

The Broad Institute, Inc.

Small type ii-d cas proteins and methods of use thereof

EP3872190A1

( en )

2020-02-26

2021-09-01

Antibodies-Online GmbH

A method of using cut&run or cut&tag to validate crispr-cas targeting

CA3177481A1

( en )

2020-05-08

2021-11-11

David R. Liu

Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

EP4001429A1

( en )

2020-11-16

2022-05-25

Antibodies-Online GmbH

Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)

<a href="/patent/WO2

Crispr having or associated with destabilization domains — The Broad Institute, Inc. (US20260152731A1)

Analyze & explore related research in Conceptio

Related documents